The industry leader’s biggest buy since Covidien gets it into robots, but direct competition with Intuitive is unlikely.
The tiny biotech has wasted no time in jumping on the oncolytic virus deal-making bandwagon, but dilution is nevertheless still likely.
Concert hopes to give Pfizer a run for its money in alopecia, while Reata looks to continue its renaissance with more Phoenix data.
Limiting abuse and reducing risks are the differentiating factors for projects from Kempharm and Supernus.
Voxeleron is, like Google’s related company Deepmind, using artificial intelligence to analyse ocular images. Unlike Deepmind, it is employing a targeted approach.
Fibrogen’s roxadustat has its first European win from the Alps trial, but the most important event is still to come.
The company’s plan to cut jobs and look at external deals could be a sign that it is becoming more like other big pharmas.
A US complete response letter leaves Ruconest at the mercy of rivals like Shire.
Positive phase II data delight investors, but Madrigal Pharmaceuticals leads in the race to market.
After buying Avexis for $8.7bn to access a potentially transformative treatment for spinal muscular atrophy, data approaches from Novartis.
The company’s stock slides 12% on fears that the goalposts in its all-important Unity-CLL trial are being moved.
Bristol-Myers Squibb is ahead in a new oral class that could bring similar efficacy to current injectables for autoimmune diseases – but Pfizer seems less keen.
Competition in the CGRP migraine space has left both Teva and Amgen willing to take hits on sales to hook new patients.
As Allogene moves to follow Autolus onto the public markets, its IPO document could give hope that Cellectis’s allogeneic assets will at long last make meaningful…
Promising mid-stage data in a third indication for efgartigimod have given the Belgian company another boost.
Galapagos needs to impress with its cystic fibrosis triplet to have a hope of catching Vertex, while Abbott needs the Coapt study of MitraClip to reach a different…
Apple has obtained its first FDA clearance, putting the Apple Watch on the same footing as Alivecor’s KardiaBand – but the smaller group is fighting back.
A genome editing tie-up between Gilead and Precision Biosciences, and promising early data with Arrowhead’s RNA interference project, are two novel approaches in hep B.
Pfizer hedging its bets in the Javelin Renal 101 study makes no difference as the trial reads out positively anyway
Amgen’s AMG 420 yielded early but spectacular remissions, leaving Boehringer Ingelheim with egg on its face.